Chlorambucil and malignancy

Ophthalmology

Volumn 117, Issue 7, 2010, Pages

  Birnbaum, Andrea D ^a   Oh, Frederick ^a   Sahin, Ozlem ^a   Little, Deborah M ^a   Tessler, Howard H ^a   Goldstein, Debra A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMBUCIL;

CANCER RISK; COLON CANCER; HUMAN; KIDNEY CARCINOMA; LETTER; LYMPHOMA; MORTALITY; PREVALENCE; PRIORITY JOURNAL; SKIN CANCER; UVEITIS;

EID: 77954330185     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2010.03.023     Document Type: Letter

References (5)

1. D.A. Goldstein, F.A. Fontanilla, and S. Kaul Long-term follow-up of patients treated with short-term high-dose chlorambucil for sight-threatening ocular inflammation Ophthalmology 109 2002 370 377
2. Horner MJ, Ries LAG, Krapcho M, et al. SEER Cancer Statistics Review, 19752006, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/ 1975-2006/, based on November 2008 SEER data submission. Accessed on SEER web site, 2009.
3. V.A. Morrison, K.R. Rai, and B.L. Peterson Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011 J Clin Oncol 20 2002 3878 3884
4. T.G. Sourlingas, and K.E. Sekeri-Pataryas S and G2 phase histone biosynthesis of HEp-2 cells after the influence of the bisalkylating agent, chlorambucil Biochem Mol Biol Int 42 1997 1103 1114
5. I. Sturm, A.G. Bosanquet, and S. Hermann Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy Cell Death Differ 10 2003 477 484